Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).
[en] OBJECTIVES: There is an important need to evaluate therapeutic approaches for osteoarthritis (OA) in terms of cost-effectiveness as well as efficacy. METHODS: The ESCEO expert working group met to discuss the epidemiological and economic evidence that justifies the increasing concern of the impact of this disease and reviewed the current state-of-the-art in health economic studies in this field. RESULTS: OA is a debilitating disease; it is increasing in frequency and is associated with a substantial and growing burden on society, in terms of both burden of illness and cost of illness. Economic evaluations in this field are relatively rare, and those that do exist, show considerable heterogeneity of methodological approach (such as indicated population, comparator, decision context and perspective, time horizon, modeling and outcome measures used). This heterogeneity makes comparisons between studies problematic. CONCLUSIONS: Better adherence to guidelines for economic evaluations is needed. There was strong support for the definition of a reference case and for what might constitute "standard optimal care" in terms of best clinical practice, for the control arms of interventional studies.
Disciplines :
General & internal medicine
Author, co-author :
Hiligsmann, Mickaël ; Université de Liège - ULiège > Département des sciences de la santé publique > Département des sciences de la santé publique
Cooper, Cyrus
Arden, Nigel
Boers, Maarten
Branco, Jaime C.
Luisa Brandi, Maria
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Guillemin, Francis
Hochberg, Marc C.
Hunter, David J.
Kanis, John A.
Kvien, Tore K.
Laslop, Andrea
Pelletier, Jean-Pierre
Pinto, Daniel
Reiter-Niesert, Susanne
Rizzoli, Rene
Rovati, Lucio C.
Severens, Johan L. Hans
Silverman, Stuart
Tsouderos, Yannis
Tugwell, Peter
REGINSTER, Jean-Yves ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).
Publication date :
2013
Journal title :
Seminars in Arthritis and Rheumatism
ISSN :
0049-0172
eISSN :
1532-866X
Publisher :
W.B. Saunders, Philadelphia, United States - Pennsylvania
Volume :
43
Issue :
3
Pages :
303-313
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
(c) 2013 The Authors. Published by Elsevier HS Journals, Inc. All rights reserved.
Committee For Medicinal Products for Human use (CHMP). Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis. CPMP/EWP/784/97 Rev. 1. 2010. European Medicines Agency, 20-1-2010.
Leskinen J., Eskelinen A., Huhtala H., Paavolainen P., Remes V. The incidence of knee arthroplasty for primary osteoarthritis grows rapidly among baby boomers: a population-based study in Finland. Arthritis Rheum 2012, 64(2):423-428.
Katz J.N. Total joint replacement in osteoarthritis. Best Pract Res Clin Rheumatol 2006, 20(1):145-153.
Hiligsmann M., Reginster J.Y. The economic weight of osteoarthritis in Europe. Medicographia 2013, 35:197-202.
Roddy E., Doherty M. Changing life-styles and osteoarthritis: what is the evidence?. Best Pract Res Clin Rheumatol 2006, 20(1):81-97.
Pereira D., Peleteiro B., Araujo J., Branco J., Santos R.A., Ramos E. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage 2011, 19(11):1270-1285.
Altman R., Alarcon G., Appelrouth D., Bloch D., Borenstein D., Brandt K., et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990, 33(11):1601-1610.
Altman R., Alarcon G., Appelrouth D., Bloch D., Borenstein D., Brandt K., et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991, 34(5):505-514.
Bijlsma J.W., Berenbaum F., Lafeber F.P. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011, 377(9783):2115-2126.
Nelson A.E., Jordan J.M. Defining osteoarthritis: a moving target. Osteoarthritis Cartilage 2012, 20(1):1-3.
Arden N., Nevitt M.C. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 2006, 20(1):3-25.
Valdes A.M., Doherty S., Muir K.R., Zhang W., Maciewicz R.A., Wheeler M., et al. Genetic contribution to radiographic severity in osteoarthritis of the knee. Ann Rheum Dis 2012, 71(9):1537-1540.
Vos T., Flaxman A.D., Naghavi M., Lozano R., Michaud C., Ezzati M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013, 380(9859):2163-2196.
Altman R.D., Abadie E., Avouac B., Bouvenot G., Branco J., Bruyere O., et al. Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoarthritis Cartilage 2005, 13(1):13-19.
OECD. Health at a glance 2011. OECD indicators. OECD Publishing 2011. http://dx.doi.org/10.1787/health_glance-2011-en.
Piscitelli P., Iolascon G., Di T.G., Bizzi E., Chitano G., Argentiero A., et al. Socioeconomic burden of total joint arthroplasty for symptomatic hip and knee osteoarthritis in the Italian population: a 5-year analysis based on hospitalization records. Arthritis Care Res (Hoboken) 2012, 64(9):1320-1327.
Kurtz S.M., Lau E., Ong K., Zhao K., Kelly M., Bozic K.J. Future young patient demand for primary and revision joint replacement: national projections from 2010 to 2030. Clin Orthop Relat Res 2009, 467(10):2606-2612.
Tarride J.E., Haq M., O'Reilly D.J., Bowen J.M., Xie F., Dolovich L., et al. The excess burden of osteoarthritis in the province of Ontario, Canada. Arthritis Rheum 2012, 64(4):1153-1161.
Losina E., Walensky R.P., Reichmann W.M., Holt H.L., Gerlovin H., Solomon D.H., et al. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med 2011, 154(4):217-226.
Ethgen O., Bruyere O., Richy F., Dardennes C., Reginster J.Y. Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am 2004, 86-A(5):963-974.
Bruyere O., Ethgen O., Neuprez A., Zegels B., Gillet P., Huskin J.P., et al. Health-related quality of life after total knee or hip replacement for osteoarthritis: a 7-year prospective study. Arch Orthop Trauma Surg 2012, 132(11):1583-1587.
Losina E., Walensky R.P., Kessler C.L., Emrani P.S., Reichmann W.M., Wright E.A., et al. Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med 2009, 169(12):1113-1121.
Fordham R., Skinner J., Wang X., Nolan J. The economic benefit of hip replacement: a 5-year follow-up of costs and outcomes in the Exeter Primary Outcomes Study. BMJ Open 2012, 2(3):e000752.
Nuesch E., Dieppe P., Reichenbach S., Williams S., Iff S., Juni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. Br Med J 2011, 342:d1165. 10.1136/bmj.d1165.:d1165.
Woolf A.D., Erwin J., March L. The need to address the burden of musculoskeletal conditions. Best Pract Res Clin Rheumatol 2012, 26(2):183-224.
March L.M., Bachmeier C.J. Economics of osteoarthritis: a global perspective. Baillieres Clin Rheumatol 1997, 11(4):817-834.
Chen A., Gupte C., Akhtar K., Smith P., Cobb J. The global economic cost of osteoarthritis: how the UK Compares. Arthritis 2012, 2012:698709. [Epubat2012 Oct 2.:698709]. 10.1155/2012/698709.
Rosenthal J.A., Lu X., Cram P. Availability of Consumer Prices From US Hospitals for a Common Surgical Procedure. J Am Med Assoc Intern Med 2013, 11:1-6.
Murphy L., Helmick C.G. The impact of osteoarthritis in the United States: a population-health perspective. Am J Nurs 2012, 112(3 Suppl. 1):S13-S19.
Herbold J.A., Bonistall K., Walsh M.B. Rehabilitation following total knee replacement, total hip replacement, and hip fracture: a case-controlled comparison. J Geriatr Phys Ther 2011, 34(4):155-160.
Westby M.D. Rehabilitation and total joint arthroplasty. Clin Geriatr Med 2012, 28(3):489-508.
Dong H., Buxton M. Early assessment of the likely cost-effectiveness of a new technology: a Markov model with probabilistic sensitivity analysis of computer-assisted total knee replacement. Int J Technol Assess Health Care 2006, 22(2):191-202.
Daigle M.E., Weinstein A.M., Katz J.N., Losina E. The cost-effectiveness of total joint arthroplasty: a systematic review of published literature. Best Pract Res Clin Rheumatol 2012, 26(5):649-658.
Jenkins P.J., Clement N.D., Hamilton D.F., Gaston P., Patton J.T., Howie C.R. Predicting the cost-effectiveness of total hip and knee replacement: a health economic analysis. Bone Joint J 2013, 95-B(1):115-121.
Gabriel S.E., Crowson C.S., Campion M.E., O'Fallon W.M. Direct medical costs unique to people with arthritis. J Rheumatol 1997, 24(4):719-725.
MacLean C.H., Knight K., Paulus H., Brook R.H., Shekelle P.G. Costs attributable to osteoarthritis. J Rheumatol 1998, 25(11):2213-2218.
Mapel D.W., Shainline M., Paez K., Gunter M. Hospital, pharmacy, and outpatient costs for osteoarthritis and chronic back pain. J Rheumatol 2004, 31(3):573-583.
Dibonaventura M.D., Gupta S., McDonald M., Sadosky A., Pettitt D., Silverman S. Impact of self-rated osteoarthritis severity in an employed population: cross-sectional analysis of data from the national health and wellness survey. Health Qual Life Outcomes 2012, 10:30. 10.1186/1477-7525-10-30.:30-10.
Hermans J., Koopmanschap M.A., Bierma-Zeinstra S.M., van Linge J.H., Verhaar J.A., Reijman M., et al. Productivity costs and medical costs among working patients with knee osteoarthritis. Arthritis Care Res (Hoboken) 2012, 64(6):853-861.
Zhang W., Doherty M., Leeb B.F., Alekseeva L., Arden N.K., Bijlsma J.W., et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007, 66(3):377-388.
Zhang W., Doherty M., Arden N., Bannwarth B., Bijlsma J., Gunther K.P., et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005, 64(5):669-681.
Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16(2):137-162.
NICE: National Institute for Health and Clinical Excellence. Osteoarthritis: The care and management of oeteoarthritis in adults. 2008. http://guidance.nice.org.uk/CG59/NICEGuidance/pdf/English.
Hochberg M.C., Altman R.D., April K.T., Benkhalti M., Guyatt G., McGowan J., et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012, 64(4):465-474.
Eichler H.G., Kong S.X., Gerth W.C., Mavros P., Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value Health 2004, 7(5):518-528.
Taylor R.S., Drummond M.F., Salkeld G., Sullivan S.D. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. Br Med J 2004, 329(7472):972-975.
Rascati K.L. Essentials of Pharmacoeconomics 2009, Wolters Kluwer/Lippincott, Williams & Wilkins, Philadelphia.
Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B., Stoddart G.L. Methods for the Economic Evaluation of Health Care Programmes 2005, Oxford University Press, Oxford, UK. 3rd ed.
Bellamy N., Kirwan J., Boers M., Brooks P., Strand V., Tugwell P., et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 1997, 24(4):799-802.
Ruchlin H.S., Insinga R.P. A review of health-utility data for osteoarthritis: implications for clinical trial-based evaluation. Pharmacoeconomics 2008, 26(11):925-935.
Dougados M., Leclaire P., van der Heijde D., Bloch D.A., Bellamy N., Altman R.D. Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage 2000, 8(6):395-403.
Bellamy N., Bell M.J., Goldsmith C.H., Pericak D., Walker V., Raynauld J.P., et al. Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis. Ann Rheum Dis 2005, 64(6):881-885.
Chen Y.F., Jobanputra P., Barton P., Bryan S., Fry-Smith A., Harris G., et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008, 12(11):1-278. (iii).
Harrison M.J., Bansback N.J., Marra C.A., Drummond M., Tugwell P.S., Boonen A. Valuing health for clinical and economic decisions: directions relevant for rheumatologists. J Rheumatol 2011, 38(8):1770-1775.
Brennan A., Akehurst R. Modelling in health economic evaluation. What is its place? What is its value?. Pharmacoeconomics 2000, 17(5):445-459.
Buxton M.J., Drummond M.F., Van Hout B.A., Prince R.L., Sheldon T.A., Szucs T., et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997, 6(3):217-227.
Sculpher M.J., Claxton K., Drummond M., McCabe C. Whither trial-based economic evaluation for health care decision making?. Health Econ 2006, 15(7):677-687.
Torrance G.W. Designing and conduction cost-utility analyses. Quality of Life and Pharmacoeconomics in Clinical Trials 1996, 1105-1111. Lippincott-Raven, Philadelphia. 2nd ed. B. Spilker (Ed.).
Raftery J. Review of NICE's recommendations, 1999-2005. Br Med J 2006, 332(7552):1266-1268.
Cleemput I., Neyt M., Thiry N., De L.C., Leys M. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Technol Assess Health Care 2011, 27(1):71-76.
World Health Organization. Macroeconomics and Health: Investing in Health for Economic Development. WHO 2011 [cited 2013 Mar 25].
Strom O., Borgstrom F., Kanis J.A., Compston J., Cooper C., McCloskey E.V., et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2011, 6(1-2):59-155.
Dunlop D.D., Song J., Semanik P.A., Sharma L., Chang R.W. Physical activity levels and functional performance in the osteoarthritis initiative: a graded relationship. Arthritis Rheum 2011, 63(1):127-136.
Cottrell E., Roddy E., Foster N.E. The attitudes, beliefs and behaviours of GPs regarding exercise for chronic knee pain: a systematic review. BMC Fam Pract 2010, 11:4. 10.1186/1471-2296-11-4.:4-11.
Dunlop D.D., Song J., Semanik P.A., Chang R.W., Sharma L., Bathon J.M., et al. Objective physical activity measurement in the osteoarthritis initiative: are guidelines being met?. Arthritis Rheum 2011, 63(11):3372-3382.
Manning V.L., Hurley M.V., Scott D.L., Bearne L.M. Are patients meeting the updated physical activity guidelines? Physical activity participation, recommendation, and preferences among inner-city adults with rheumatic diseases. J Clin Rheumatol 2012, 18(8):399-404.
Song J., Hochberg M.C., Chang R.W., Hootman J.M., Manheim L.M., Lee J., et al. Racial/ethnic differences in physical activity guideline attainment among participants in the osteoarthritis initiative. Arthritis Care Res (Hoboken) 2012, 17:10.
Pinto D., Robertson M.C., Hansen P., Abbott J.H. Cost-effectiveness of nonpharmacologic, nonsurgical interventions for hip and/or knee osteoarthritis: systematic review. Value Health 2012, 15(1):1-12.
Ofman J.J., Sullivan S.D., Neumann P.J., Chiou C.F., Henning J.M., Wade S.W., et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm 2003, 9(1):53-61.
van Tulder M., Furlan A., Bombardier C., Bouter L. Updated method guidelines for systematic reviews in the cochrane collaboration back review group. Spine (Phila Pa 1976, 28(12):1290-1299.
Richardson G., Hawkins N., McCarthy C.J., Mills P.M., Pullen R., Roberts C., et al. Cost-effectiveness of a supplementary class-based exercise program in the treatment of knee osteoarthritis. Int J Technol Assess Health Care 2006, 22(1):84-89.
Cochrane T., Davey R.C., Matthes Edwards S.M. Randomised controlled trial of the cost-effectiveness of water-based therapy for lower limb osteoarthritis. Health Technol Assess 2005, 9(31):iii-xi. (1).
Reinhold T., Witt C.M., Jena S., Brinkhaus B., Willich S.N. Quality of life and cost-effectiveness of acupuncture treatment in patients with osteoarthritis pain. Eur J Health Econ 2008, 9(3):209-219.
Coupe V.M., Veenhof C., van Tulder M.W., Dekker J., Bijlsma J.W., Van den Ende C.H. The cost effectiveness of behavioural graded activity in patients with osteoarthritis of hip and/or knee. Ann Rheum Dis 2007, 66(2):215-221.
Hurley M.V., Walsh N.E., Mitchell H.L., Pimm T.J., Williamson E., Jones R.H., et al. Economic evaluation of a rehabilitation program integrating exercise, self-management, and active coping strategies for chronic knee pain. Arthritis Rheum 2007, 57(7):1220-1229.
Jessep S.A., Walsh N.E., Ratcliffe J., Hurley M.V. Long-term clinical benefits and costs of an integrated rehabilitation programme compared with outpatient physiotherapy for chronic knee pain. Physiotherapy 2009, 95(2):94-102.
Lord J., Victor C., Littlejohns P., Ross F.M., Axford J.S. Economic evaluation of a primary care-based education programme for patients with osteoarthritis of the knee. Health Technol Assess 1999, 3(23):1-55.
Patel A., Buszewicz M., Beecham J., Griffin M., Rait G., Nazareth I., et al. Economic evaluation of arthritis self management in primary care. Br Med J 2009, 339:b3532. 10.1136/bmj.b3532.:b3532.
Coupé V.M., Veenhof C., van Tulder M.W., Dekker J., Bijlsma J.W., Van den Ende C.H. The cost effectiveness of behavioural graded activity in patients with osteoarthritis of hip and/or knee. Ann Rheum Dis 2007, 66(2):215-221.
O'Brien B.J., Gertsen K., Willan A.R., Faulkner L.A. Is there a kink in consumers' threshold value for cost-effectiveness in health care?. Health Econ 2002, 11(2):175-180.
Severens J.L., Brunenberg D.E., Fenwick E.A., O'Brien B., Joore M.A. Cost-effectiveness acceptability curves and a reluctance to lose. Pharmacoeconomics 2005, 23(12):1207-1214.
Loew L., Brosseau L., Wells G.A., Tugwell P., Kenny G.P., Reid R., et al. Ottawa panel evidence-based clinical practice guidelines for aerobic walking programs in the management of osteoarthritis. Arch Phys Med Rehabil 2012, 93(7):1269-1285.
Brosseau L., Wells G.A., Tugwell P., Egan M., Dubouloz C.J., Casimiro L., et al. Ottawa Panel evidence-based clinical practice guidelines for the management of osteoarthritis in adults who are obese or overweight. Phys Ther 2011, 91(6):843-861.
Maetzel A., Krahn M., Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003, 49(3):283-292.
Black C., Clar C., Henderson R., MacEachern C., McNamee P., Quayyum Z., et al. The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation. Health Technol Assess 2009, 13(52):1-148.
Loyd M., Rublee D., Jacobs P. An economic model of long-term use of celecoxib in patients with osteoarthritis. BMC Gastroenterol 2007, 7(25):25.
Kamath C.C., Kremers H.M., Vanness D.J., O'Fallon W.M., Cabanela R.L., Gabriel S.E. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value Health 2003, 6(2):144-157.
Spiegel B.M., Targownik L., Dulai G.S., Gralnek I.M. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003, 138(10):795-806.
Moore A., Phillips C., Hunsche E., Pellissier J., Crespi S. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. Pharmacoeconomics 2004, 22(10):643-660.
Yen Z.S., Lai M.S., Wang C.T., Chen L.S., Chen S.C., Chen W.J., et al. Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan. J Rheumatol 2004, 31(9):1797-1803.
Marshall D.A., Strauss M.E., Pericak D., Buitendyk M., Codding C., Torrance G.W. Economic evaluation of controlled-release oxycodone vs oxycodone-acetaminophen for osteoarthritis pain of the hip or knee. Am J Manag Care 2006, 12(4):205-214.
Ward A., Bozkaya D., Fleischmann J., Dubois D., Sabatowski R., Caro J.J. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone. Curr Med Res Opin 2007, 23(10):2333-2345.
Al M.J., Maniadakis N., Grijseels E.W., Janssen M. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands. Value Health 2008, 11(4):589-599.
Contreras-Hernandez I., Mould-Quevedo J.F., Torres-Gonzalez R., Goycochea-Robles M.V., Pacheco-Dominguez R.L., Sanchez-Garcia S., et al. Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors. Cost Effectiveness Resour Allocation 2008, 6:21. 10.1186/1478-7547-6-21.:21-6.
Bessette L., Risebrough N., Mittmann N., Roussy J.P., Ho J., Zlateva G. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective. J Med Econ 2009, 12(3):246-258.
Latimer N., Lord J., Grant R.L., O'Mahony R., Dickson J., Conaghan P.G. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. Br Med J 2009, 339:b2538. 10.1136/bmj.b2538.:b2538.
Bruyere O., Scholtissen S., Neuprez A., Hiligsmann M., Toukouki A., Reginster J.Y. Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis. J Med Econ 2009, 12(4):356-360.
Scholtissen S., Bruyere O., Neuprez A., Severens J.L., Herrero-Beaumont G., Rovati L., et al. Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. Int J Clin Pract 2010, 64(6):756-762.
Brereton N., Winn B., Akehurst R. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial. J Med Econ 2012, 15(3):465-472.
Elders M.J. The increasing impact of arthritis on public health. J Rheumatol Suppl 2000, 60:6-8.
Hunsche E., Chancellor J.V., Bruce N. The burden of arthritis and nonsteroidal anti-inflammatory treatment. A European literature review. Pharmacoeconomics 2001, 19(Suppl. 1):1-15.
Gabriel S.E., Tugwell P., Drummond M. Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology. Ann Rheum Dis 2002, 61(4):370-373.
Ramsey S., Willke R., Briggs A., Brown R., Buxton M., Chawla A., et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005, 8(5):521-533.
Berger M.L., Dreyer N., Anderson F., Towse A., Sedrakyan A., Normand S.L. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. Value Health 2012, 15(2):217-230.
Drummond M., Maetzel A., Gabriel S., March L. Towards a reference case for use in future economic evaluations of interventions in osteoarthritis. J Rheumatol Suppl 2003, 68:26-30.
Gabriel S., Drummond M., Maetzel A., Boers M., Coyle D., Welch V., et al. OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 2003, 30(4):886-890.
Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62(12):1145-1155.
Guyatt G.H., Oxman A.D., Schunemann H.J., Tugwell P., Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011, 64(4):380-382.
Thornton J., Alderson P., Tan T., Turner C., Latchem S., Shaw E., et al. Introducing GRADE across the NICE clinical guideline program. J Clin Epidemiol 2013, 66(2):124-131.
Husereau D., Drummond M., Petrou S., Carswell C., Moher D., Greenberg D., et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Br Med J 2013, 346:1.
Brunetti M., Shemilt I., Pregno S., Vale L., Oxman A.D., Lord J., et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol 2013, 66(2):140-150.
Smelter E., Hochberg M.C. New treatments for osteoarthritis. Curr Opin Rheumatol 2013, 25(3):310-316.
Maillefert J.F., Dougados M. Is time to joint replacement a valid outcome measure in clinical trials of drugs for osteoarthritis?. Rheum Dis Clin North Am 2003, 29(4):831-845.
Gossec L., Hawker G., Davis A.M., Maillefert J.F., Lohmander L.S., Altman R., et al. OMERACT/OARSI initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. J Rheumatol 2007, 34(6):1432-1435.
Ghomrawi H.M., Schackman B.R., Mushlin A.I. Appropriateness criteria and elective procedures-total joint arthroplasty. N Engl J Med 2012, 367(26):2467-2469.
Carr A.J., Robertsson O., Graves S., Price A.J., Arden N.K., Judge A., et al. Knee replacement. Lancet 2012, 379(9823):1331-1340.
